Osmotics

Osmotica Pharmaceuticals was a specialty pharmaceutical company that utilized its proprietary Osmodex drug delivery system to develop and commercialize hard-to-replicate dosage forms. The company's portfolio spanned various therapeutic areas, including neurology, ophthalmology, and psychiatry, featuring both branded and generic products. Its most significant achievement was the FDA approval of Upneeq (oxymetazoline hydrochloride ophthalmic solution) for the treatment of acquired blepharoptosis. Following a strategic shift in 2021, the company sold its legacy portfolio to Alora Pharmaceuticals and rebranded as RVL Pharmaceuticals to focus on aesthetics and ophthalmology, before eventually facing financial restructuring and bankruptcy in late 2023.